Plain English Breakdown
The exact nature of the tests and information that health care service plans and insurance companies cannot request is not specified in the provided official source material.
Hepatitis C Treatment: No Prior Authorization
AB-1843 stops health care plans and insurers from requiring prior approval before giving out direct-acting antiviral drugs needed to treat hepatitis C, but it doesn't force them to cover all similar drugs without approval.
What This Bill Does
- It prohibits health care service plans and insurance companies from requiring prior authorization for direct-acting antiviral drugs used to treat hepatitis C that are medically necessary.
- These provisions do not require health care service plans or insurers to cover all therapeutically equivalent versions of these drugs without prior authorization.
- Health care service plans and insurers must align their clinical criteria for hepatitis C treatment with current guidelines set by medical groups like the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
- It prohibits health care service plans and insurance companies from requesting certain tests or information when deciding if they will cover hepatitis C treatment.
Who It Names or Affects
- People with hepatitis C who need direct-acting antiviral drugs.
- Health care service plans and insurance companies that provide coverage for these drugs.
Terms To Know
- Prior Authorization
- A process where a health plan or insurer needs to approve a drug before it can be given to a patient.
- Direct-Acting Antiviral Drugs
- Medicines used to treat hepatitis C by stopping the virus from spreading in the body.
Limits and Unknowns
- The bill does not require health plans or insurers to cover all similar drugs without prior authorization.
- It is unclear how this will affect people who already have restrictions on their coverage for hepatitis C treatment.